Proteomic Approaches for Urine Biomarker Discovery in Bladder Cancer

Part of the Translational Bioinformatics book series (TRBIO, volume 3)


Bladder cancer is the most common urological cancer with higher incidence rate in the endemic areas of blackfoot disease (BFD) in southern Taiwan. Urine, a blood filtrate produced by the urinary system, is readily collected and is an important source of information for bladder cancers because it is directly exposed to bladder epithelium. Global analysis of the human urinary proteome is important for understanding urinary tract diseases. The aim of this chapter was to utilize the proteomic approach to establish urinary protein patterns of bladder cancer. The experimental results showed that most patients with bladder cancer had proteinuria or albuminuria. In the proteomic analysis, the urinary proteome was identified by nano-high-performance liquid chromatography electrospray ionization tandem mass spectrometry (nano-HPLC-ESI-MS/MS) followed by peptide fragmentation pattern analysis. ADAM28, identified by proteomic approaches and confirmed by ELISA, showed significant differences compared with normal individuals. The upregulation of urinary ADAM28 in bladder cancer was revealed, so it may be a biomarker of bladder cancer.


Proteomics Bladder cancer Urinary protein Protein identification Biomarker 



We are thankful to S. Sheldon MT (ASCP) of Oklahoma University Medical Center Edmond (USA) for fruitful discussions. This work was supported by research grants NSC-099-2811-E-22-002 and NSC-100-2320-B-037-007-MY3 from the National Science Council and NSYSUKMU 101-015 from NSYSU-KMU Joint Research Project, Taiwan, Republic of China.


  1. Aaboe M, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 2006;66(7):3434–42.PubMedCrossRefGoogle Scholar
  2. Bane BL, Rao JY. Pathology and staging of bladder cancer. Semin Oncol. 1996;23(5):549–70.Google Scholar
  3. Beetham R, Cattell WR. Proteinuria: pathophysiology, significance and recommendations for measurement in clinical practice. Ann Clin Biochem. 1993;30(Pt 5):425–34.PubMedGoogle Scholar
  4. Castagna A, et al. Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res. 2005;4(6):1917–30.PubMedCrossRefGoogle Scholar
  5. Celis JE, et al. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol. 1996;155(6):2105–12.PubMedCrossRefGoogle Scholar
  6. Celis JE, et al. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics. 2002;1(4):269–79.PubMedCrossRefGoogle Scholar
  7. Celis JE, et al. Impact of proteomics on bladder cancer research. Pharmacogenomics. 2004;5(4):381–94.PubMedCrossRefGoogle Scholar
  8. Delanghe J. Use of specific urinary proteins as diagnostic markers for renal disease. Acta Clin Belg. 1997;52(3):148–53.PubMedGoogle Scholar
  9. Delden CJ, et al. Heparinization of gas plasma-modified polystyrene surfaces and the interactions of these surfaces with proteins studied with surface plasmon resonance. Biomaterials. 1997;18(12):845–52.PubMedCrossRefGoogle Scholar
  10. Fujii K, et al. Multidimensional protein profiling technology and its application to human plasma proteome. J Proteome Res. 2004;3(4):712–18.PubMedCrossRefGoogle Scholar
  11. Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol. 1998;16(1):17–22.PubMedGoogle Scholar
  12. Guo Y, et al. 1-DE MS and 2-D LC-MS analysis of the mouse bronchoalveolar lavage proteome. Proteomics. 2005;5(17):4608–24.PubMedCrossRefGoogle Scholar
  13. Hamler RL, et al. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics. 2004;4(3):562–77.PubMedCrossRefGoogle Scholar
  14. Hampel DJ, et al. Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. J Am Soc Nephrol. 2001;12(5):1026–35.PubMedGoogle Scholar
  15. Hong SS, Kwon SW. Profiling of urinary proteins by nano-high performance liquid chromatography/tandem mass spectrometry. J Liq Chromatogr Relat Technol. 2005;28(6):805–22.CrossRefGoogle Scholar
  16. Jaffe JD, Berg HC, Church GM. Proteogenomic mapping as a complementary method to perform genome annotation. Proteomics. 2004;4(1):59–77.PubMedCrossRefGoogle Scholar
  17. Jürgens M, et al. Towards characterization of the human urinary peptidome. Comb Chem High Throughput Screen. 2005;8(8):757–65.PubMedCrossRefGoogle Scholar
  18. Kageyama S, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004;50(5):857–66.PubMedCrossRefGoogle Scholar
  19. Kang IK, et al. Immobilization of proteins on poly(methyl methacrylate) films. Biomaterials. 1993;14(10):787–92.PubMedCrossRefGoogle Scholar
  20. Konety BR, Williams RD. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int. 2004;94(1):18–21.PubMedCrossRefGoogle Scholar
  21. Kuijpers AJ, et al. In vitro and in vivo evaluation of gelatin-chondroitin sulphate hydrogels for controlled release of antibacterial proteins. Biomaterials. 2000;21(17):1763–72.PubMedCrossRefGoogle Scholar
  22. Kuroda H, et al. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Int J Cancer. 2010;127(8):1844–56.PubMedCrossRefGoogle Scholar
  23. Lafitte D, et al. Optimized preparation of urine samples for two-dimensional electrophoresis and initial application to patient samples. Clin Biochem. 2002;35(8):581–9.PubMedCrossRefGoogle Scholar
  24. Lee SW, Lee KI, Kim JY. Revealing urologic diseases by proteomic techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;815(1–2):203–13.PubMedGoogle Scholar
  25. Lwaki H, et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 2004;95(12):955–61.CrossRefGoogle Scholar
  26. Marshall T, William KM. Clinical analysis of human urinary proteins using high resolution electrophoretic methods. Electrophoresis. 1998;19(10):1752–70.PubMedCrossRefGoogle Scholar
  27. Mitsui Y, et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006;66(20):9913–20.PubMedCrossRefGoogle Scholar
  28. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98(5):621–8.PubMedCrossRefGoogle Scholar
  29. Mochizuki S, Okada Y. ADAM28 as a target for human cancers. Curr Pharm Des. 2009;15(20):2349–58.PubMedCrossRefGoogle Scholar
  30. O’Donovan C, et al. High-quality protein knowledge resource: SWISS-PROT and TrEMBL. Brief Bioinform. 2002;3(3):275–84.PubMedCrossRefGoogle Scholar
  31. Oh J, et al. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics. 2004;4(11):3485–97.PubMedCrossRefGoogle Scholar
  32. Ohtsuka T, et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer. 2006;118(2):263–73.PubMedCrossRefGoogle Scholar
  33. Okada Y. Modulation of the microenvironment and adhesion of cancer cells by ADAMs (a disintegrin and metalloproteinase). Verh Dtsch Ges Pathol. 2007;91:29–38.PubMedGoogle Scholar
  34. Park MR, et al. Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics. 2006;6(3):1066–76.PubMedCrossRefGoogle Scholar
  35. Pieper R, et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004;4(4):1159–74.PubMedCrossRefGoogle Scholar
  36. Poliness AE, et al. Proteomic approaches in endometriosis research. Proteomics. 2004;4(7):1897–902.PubMedCrossRefGoogle Scholar
  37. Ramakumar S, et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999;161(2):388–94.PubMedCrossRefGoogle Scholar
  38. Rocks N, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90(2):369–79.PubMedCrossRefGoogle Scholar
  39. Ru OC, et al. Proteomic profiling of human urine using multidimensional protein identification technology. J Chromatogr A. 2006;1111(2):166–74.PubMedCrossRefGoogle Scholar
  40. Smith G, et al. Development of a high-throughput method for preparing human urine for two-dimensional electrophoresis. Proteomics. 2005;5(9):2315–18.PubMedCrossRefGoogle Scholar
  41. Tantipaiboonwong P, et al. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics. 2005;5(4):1140–9.PubMedCrossRefGoogle Scholar
  42. Thongboonkerd V, Malasit P. Renal and urinary proteomics: current applications and challenges. Proteomics. 2005;5(4):1033–42.PubMedCrossRefGoogle Scholar
  43. Thongboonkerd V, et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002;62(4):1461–9.PubMedCrossRefGoogle Scholar
  44. Thongboonkerd V, et al. Sodium loading changes urinary protein excretion: a proteomic analysis. Am J Physiol Renal Physiol. 2003;284(6):F1155–63.PubMedGoogle Scholar
  45. Tolson JP, et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics. 2006;6(2):697–708.PubMedCrossRefGoogle Scholar
  46. Tyan YC, et al. Assessment and characterization of degradation effect for the varied degrees of ultra-violet radiation onto the collagen-bonded polypropylene non-woven fabric surfaces. Biomaterials. 2002;23(1):65–76.PubMedCrossRefGoogle Scholar
  47. Tyan YC, et al. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Chim Acta. 2006;579(2):158–76.PubMedCrossRefGoogle Scholar
  48. Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422(6928):193–7.PubMedCrossRefGoogle Scholar
  49. Wilkins MR, et al. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis. 1996;17(5):830–8.PubMedCrossRefGoogle Scholar
  50. Wolters DA, Washburn MP, Yates JR. An automated multidimensional protein identification ­technology for shotgun proteomics. Anal Chem. 2001;73(23):5683–90.PubMedCrossRefGoogle Scholar
  51. Zerefos PG, et al. Characterization of the human urine proteome by preparative electrophoresis in combination with 2-DE. Proteomics. 2006;6(15):4346–55.PubMedCrossRefGoogle Scholar
  52. Zhang YF, et al. Tree analysis of mass spectral urine profiles discriminates transitional cell ­carcinoma of the bladder from noncancer patient. Clin Biochem. 2004;37(9):772–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Chemical and Materials EngineeringNational Yunlin University of Science and TechnologyYunlinTaiwan
  2. 2.Department of Medical Imaging and Radiological Sciences/Center of Excellence for Environmental Medicine/National Sun Yat-Sen University-Kaohsiung Medical University Joint Research CenterKaohsiung Medical UniversityKaohsiungTaiwan

Personalised recommendations